By Denny Jacob American depositary receipts of Avadel Pharmaceuticals rose 19% to $12.34 on revenue growth powered by sales of Lumryz in the third quarter..
$7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUPTM and more than 400 patients initiating therapy as of September 30 LUMRYZ to be added to preferred position for CVS commercial formularies effective January 1, 2024 Submitted sNDA for LUMRYZ in pediatric narcolepsy population on November 7th Management to host a conference call today at 8:30 a.m. ET DUBLI